GlassScriptPhysician profile
David J Gaskin
NPI 1952340291
$13,991.00
in general payments reported to CMS, 2019-2025
79 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $1,501 · 2021: $2,672 · 2022: $2,488 · 2023: $2,394 · 2024: $1,866 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,697 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,696.63 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,770.85 | 2020-2025 | |
| Novo Nordisk INC | $1,408.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $914.64 | 2019-2025 | Repatha, Otezla, Tepezza |
| Pfizer INC. | $805.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $730.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $709.20 | 2019-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $608.34 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Glaxosmithkline, LLC. | $566.51 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $514.59 | 2019-2021 | |
| Lilly USA, LLC | $427.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.49 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $369.01 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $353.73 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Esperion Therapeutics, INC. | $276.87 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $238.48 | 2019-2022 |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gaskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.